Primary Ciliary Dyskinesia Diagnostics Market is driven by growing awareness and availability of advanced diagnostics te

Primary ciliary dyskinesia (PCD) is a rare genetic disease characterized by defects in cilia structure or function leading to abnormal mucus clearance and recurring respiratory infections from an early age. Some key signs and symptoms associated with PCD include chronic infections of the sinuses, ears, and lungs, sinusitis, breathing difficulties, and impaired fertility in some cases. Historically, PCD was under-diagnosed due to lack of disease awareness among physicians and limited availability of advanced diagnostic tests. However, growing awareness initiatives by patient advocacy groups and introduction of advanced tools like high-speed videomicroscopy and genetic testing have enabled more accurate PCD diagnosis over the past decade.

The primary ciliary dyskinesia market is estimated to be valued at USD 538.2 Mn in 2024 and is expected to reach USD 784.5 Mn by 2031, growing at a compound annual growth rate (CAGR) of 5.5% from 2024 to 2031.

Key players: operating in the primary ciliary dyskinesia diagnostics market are Illumina, Inc., Quest Diagnostics Incorporated, Baylor Genetics, Mayo Medical Laboratories, and BioGX.

Key Takeaways

Growing demand: Rising disease prevalence coupled with increasing awareness about available diagnostic options among physicians as well as patients has been fueling demand for Primary Ciliary Dyskinesia Market globally. Various newborn screening programs have further helped in early diagnosis and timely intervention in many countries.

Global expansion: Leading diagnostics companies are focusing on expanding their geographic footprint and service offerings related to PCD testing across major markets to address the growing need. Introduction of advanced diagnostic technologies especially in developing nations will further aid market growth over the coming years.